Loading
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 27 Jul 2026 for Scribe Therapeutics, Inc., €39k.
Filing timeline
BuySaleSvetlana Lucas
Insider track record
Disclosed buys
2
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Svetlana Lucas: trading record in brief
Filings by Svetlana Lucas span 3 companies, the busiest being aTYR PHARMA Inc, Jasper Therapeutics, Inc. and Scribe Therapeutics, Inc. We count 3 filings; the first trade dates from 26 April 2023 and the latest from 23 July 2026.
The open-market record is one-sided, with 2 purchases worth €81k and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 option exercise. So far in 2026, the count stands at 1 purchase and no sales.
The latest filing, published on 27 July 2026, reports an open-market purchase of €39k in Scribe Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Svetlana Lucas
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
3,000 shares@ US$15.00Common StockSEC:0001781292-26-000007:0
Canonical exit: 21 Oct 2026 (T+90)
20,000 shares@ US$2.43100.0% of flowVoting Common StockSEC:0001213900-25-091104:0
Canonical exit: 21 Dec 2025 (T+90)
6,000 sharesCommon stockSEC:0001209191-23-026065:0
3 of 3 declarations
